Increased incidence and healthcare burden of bullous pemphigoid: A population‐based cohort study
Journal of the European Academy of Dermatology and Venereology · 06.11.2026
DOI: 10.1111/jdv.70838 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Journal of the European Academy of Dermatology and Venereology, online erschienen am 06.11.2026. Verfasst von Anna C Meyer und 9 weiteren Autor:innen. Beteiligte Einrichtung: Sanofi-Aventis Deutschland GmbH, Berlin, Germany. Die Arbeit nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Sanofi and Regeneron.
Abstract (Originalsprache)
Background
Bullous pemphigoid (BP) is the most common autoimmune blistering disease and primarily affects older adults. As societies age and the burden of age‐related diseases increases, data on BP epidemiology, treatment patterns and healthcare burden in Germany remain limited.
Objectives
To assess BP epidemiology, clinical outcomes, healthcare utilization and economic burden in adults aged ≥ 18 years in Germany.
Methods
We analysed anonymized statutory health insurance claims from 6.8 million insured individuals (2010–2023). Annual cross‐sectional analyses estimated prevalence and incidence, extrapolated to the national population. In a matched incident cohort (BP, n = 2004; controls, n = 9950), we evaluated comorbidity, mortality, healthcare resource utilization, healthcare costs and pharmacologic management over up to 2 years. Mortality and costs were analysed using regression models adjusted for age, sex, calendar year, and comorbidity.
Results
BP prevalence tripled from 0.05 to 0.14 cases per 1000 individuals between 2010 and 2023, with the steepest increase observed among individuals aged ≥ 80 years. Annual incidence ranged from 34 to 63 cases per million inhabitants. BP patients exhibited a higher comorbidity burden than matched controls (mean Elixhauser index 5.0 vs. 3.8) and increased mortality (1‐year mortality: 18.8% vs. 6.0%; adjusted incidence rate ratio (IRR) 3.09, 95% CI: 2.71–3.52). Healthcare utilization was higher among BP patients, including physician contacts (38 vs. 22 per year) and hospital admissions (3.3 vs. 0.7 per year). Topical and systemic corticosteroids were prescribed in 75% and 72% of patients, respectively; additional therapies included doxycycline (19.7%), dapsone (15.0%) and azathioprine (14.8%). Mean total healthcare costs during the first year were €20,881 for BP patients versus €5586 for controls, mainly attributable to inpatient care.
Conclusions
BP represents a growing healthcare challenge characterized by a high comorbidity burden, increased mortality and healthcare costs. Current treatment remains reliant on systemic corticosteroids, underscoring the need for safe and effective steroid‐sparing therapies.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Sanofi-Aventis Deutschland GmbH, Berlin, Germany.
- Vandage GmbH, Bielefeld, Germany.
- Clinic of Dermatology, Helix Medical Excellence Center Mainz, Mainz, Germany.
- Department of Dermatology and Allergy, Klinikum Oldenburg, Oldenburg, Germany.
- Division of Experimental Allergy and Immunodermatology, Carl von Ossietzky University of Oldenburg, Oldenburg, Germany.
- Lübecker Institute of Experimental Dermatology, University of Lübeck, Lübeck, Germany.
ORCID-Profile: Anna C Meyer, Inka Albrecht, Lena Hasemann, Jana Diekmannshemke, Oliver Damm, Daniel Gensorowsky, Julian Witte, Ulrike Raap, Enno Schmidt
Förderung
- Sanofi and Regeneron
Zitieren
APA
Meyer, A. C., Albrecht, I., Hasemann, L., Diekmannshemke, J., Damm, O., Gensorowsky, D., Witte, J., Quist, S. R., Raap, U., & Schmidt, E. (2026). Increased incidence and healthcare burden of bullous pemphigoid: A population‐based cohort study. Journal of the European Academy of Dermatology and Venereology. https://doi.org/10.1111/jdv.70838
Vancouver
Meyer AC, Albrecht I, Hasemann L, Diekmannshemke J, Damm O, Gensorowsky D, et al. Increased incidence and healthcare burden of bullous pemphigoid: A population‐based cohort study. Journal of the European Academy of Dermatology and Venereology. 2026. doi:10.1111/jdv.70838
BibTeX
@article{Meyer2026,
author = {Meyer, Anna C and Albrecht, Inka and Hasemann, Lena and Diekmannshemke, Jana and Damm, Oliver and Gensorowsky, Daniel and Witte, Julian and Quist, Sven R and Raap, Ulrike and Schmidt, Enno},
title = {Increased incidence and healthcare burden of bullous pemphigoid: A population‐based cohort study},
journal = {Journal of the European Academy of Dermatology and Venereology},
year = {2026},
doi = {10.1111/jdv.70838}
}
EUVIMED